Cargando…

ABL Tyrosine Kinase Inhibition Variable Effects on the Invasive Properties of Different Triple Negative Breast Cancer Cell Lines

The non-receptor tyrosine kinase ABL drives myeloid progenitor expansion in human chronic myeloid leukemia. ABL inhibition by the tyrosine kinase inhibitor nilotinib is a first-line treatment for this disease. Recently, ABL has also been implicated in the transforming properties of solid tumors, inc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chevalier, Clément, Cannet, Aude, Descamps, Simon, Sirvent, Audrey, Simon, Valérie, Roche, Serge, Benistant, Christine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372365/ https://www.ncbi.nlm.nih.gov/pubmed/25803821 http://dx.doi.org/10.1371/journal.pone.0118854

Ejemplares similares

Control of Tyrosine Kinase Signalling by Small Adaptors in Colorectal Cancer
por: Mevizou, Rudy, et al.
Publicado: (2019)

Src Family Tyrosine Kinases in Intestinal Homeostasis, Regeneration and Tumorigenesis
por: Sirvent, Audrey, et al.
Publicado: (2020)

The role of small adaptor proteins in the control of oncogenic signaling driven by tyrosine kinases in human cancer
por: Naudin, Cécile, et al.
Publicado: (2016)

Collagen Kinase Receptors as Potential Therapeutic Targets in Metastatic Colon Cancer
por: Lafitte, Marie, et al.
Publicado: (2020)

Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders
por: Mesa, Ruben A
Publicado: (2007)

TOM1L1 drives membrane delivery of MT1-MMP to promote ERBB2-induced breast cancer cell invasion
por: Chevalier, Clément, et al.
Publicado: (2016)

Constitutive Activity in an Ancestral Form of Abl Tyrosine Kinase
por: Aleem, Saadat U., et al.
Publicado: (2015)

Bcr-Abl tyrosine kinase inhibitors- current status
por: Mughal, Anum, et al.
Publicado: (2013)

The Csk-binding protein PAG regulates PDGF-induced Src mitogenic signaling via GM1
por: Veracini, Laurence, et al.
Publicado: (2008)

Tyrosine kinase c-Abl regulates the survival of plasma cells
por: Li, Yan-Feng, et al.
Publicado: (2017)

Abl Tyrosine Kinase Regulates Hepatitis C Virus Entry
por: Min, Saehong, et al.
Publicado: (2017)

Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
por: Carofiglio, Francesca, et al.
Publicado: (2020)

The Role of c-Abl Tyrosine Kinase in Brain and Its Pathologies
por: Motaln, Helena, et al.
Publicado: (2023)

Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
por: Takeuchi, Asako, et al.
Publicado: (2020)

A Src-Like Inactive Conformation in the Abl Tyrosine Kinase Domain
por: Levinson, Nicholas M, et al.
Publicado: (2006)

Role of the ABL tyrosine kinases in the epithelial–mesenchymal transition and the metastatic cascade
por: Luttman, Jillian Hattaway, et al.
Publicado: (2021)

Transcriptomic Analysis of Subtype-Specific Tyrosine Kinases as Triple Negative Breast Cancer Biomarkers
por: Limsakul, Praopim, et al.
Publicado: (2023)

Specific Oncogenic Activity of the Src-Family Tyrosine Kinase c-Yes in Colon Carcinoma Cells
por: Sancier, Florence, et al.
Publicado: (2011)

Src- and Abl-family kinases activate spleen tyrosine kinase to maximize phagocytosis and Leishmania infection
por: Ullah, Imran, et al.
Publicado: (2023)

Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling
por: Bieerkehazhi, Shayahati, et al.
Publicado: (2016)

Cockayne syndrome protein B interacts with and is phosphorylated by c-Abl tyrosine kinase
por: Imam, Syed Z., et al.
Publicado: (2007)

Cbl-associated protein is tyrosine phosphorylated by c-Abl and c-Src kinases
por: Fernow, Inga, et al.
Publicado: (2009)

BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
por: Cuellar, Sandra, et al.
Publicado: (2017)

c-Abl Tyrosine Kinase Adopts Multiple Active Conformational States in Solution
por: Badger, John, et al.
Publicado: (2016)

RUNX2 Phosphorylation by Tyrosine Kinase ABL Promotes Breast Cancer Invasion
por: He, Fang, et al.
Publicado: (2021)

c-Abl Tyrosine Kinase Is Required for BDNF-Induced Dendritic Branching and Growth
por: Chandía-Cristi, América, et al.
Publicado: (2023)

Src Family Tyrosine Kinase Regulates Intracellular pH in Cardiomyocytes
por: Pucéat, Michel, et al.
Publicado: (1998)

DDR1 inhibition as a new therapeutic strategy for colorectal cancer
por: Sirvent, Audrey, et al.
Publicado: (2018)

Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase Domain
por: Levinson, Nicholas M., et al.
Publicado: (2012)

Abl Tyrosine Kinase Phosphorylates Nonmuscle Myosin Light Chain Kinase to Regulate Endothelial Barrier Function
por: Dudek, Steven M., et al.
Publicado: (2010)

Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell lines
por: Lu, Liu, et al.
Publicado: (2018)

Effect of c-Abl tyrosine kinase on the cellular response to paclitaxel-induced microtubule damage
por: Nehmé, A, et al.
Publicado: (2000)

cGMP-mediated antioxidant signaling: a role for the c-Abl tyrosine kinase
por: Stephens, Robert S, et al.
Publicado: (2011)

Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia
por: de Almeida, Maria Helena, et al.
Publicado: (2014)

Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia
por: Rassi, Fuad El, et al.
Publicado: (2013)

Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase
por: Reckel, Sina, et al.
Publicado: (2017)

A Role for the Non-Receptor Tyrosine Kinase Abl2/Arg in Experimental Neuroinflammation
por: Jacobsen, Freja Aksel, et al.
Publicado: (2018)

Interaction of Abl Tyrosine Kinases with SOCS3 Impairs Its Suppressor Function in Tumorigenesis()()()
por: Feng, Riyue, et al.
Publicado: (2018)

BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
por: Haguet, Hélène, et al.
Publicado: (2018)

BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon
por: Stanchina, Michele, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9q2uc2d1ka38urhf3bpr8pn94g